<div id="readability-page-1"><p>Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Monte Rosa Therapeutics today and set a price target of $20.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Tenthoff is an analyst with an average return of <span>-8.8%</span> and a 33.95% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Arrowhead Pharmaceuticals.</p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monte Rosa Therapeutics with a $18.00 average price target.</p></div>

GLUE

<p>Piper Sandler analyst Edward Tenthoff reiterated a Buy rating for Monte Rosa Therapeutics, setting a price target of $20. The analyst has an average return of -8.8% and a 33.95% success rate. The consensus among analysts is a Strong Buy for Monte Rosa Therapeutics, with an average price target of $18.</p>

Piper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)